Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

FAST Fish Phase IIb Clinical Trial for the Treatment of Fish Allergy by Subcutaneous Immunotherapy (FASTIIb)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02382718
Recruitment Status : Completed
First Posted : March 9, 2015
Last Update Posted : June 12, 2017
Sponsor:
Collaborators:
Hospital San Carlos, Madrid
Odense University Hospital OUH Denmark
Medical Universtity of Lodz
National and Kapodistrian University of Athens
Landspitali University Hospital
National University Hospital NUHD Denmark
Universitiy Medical Centre Utrecht UMCU The Netherlands
Hospital Universitario Reina Sofia (Cordoba) Spain
Hospital Regional Universitario de Malaga Spain
Information provided by (Responsible Party):
George Stavroulakis, University of Athens

Brief Summary:
This is a phase IIb clinical trial to investigate the efficacy and safety of subcutaneous immunotherapy with a modified parvalbumin called mCyp c 1 for the treatment of fish allergy to subjects allergic to fish.

Condition or disease Intervention/treatment Phase
Food Allergy to Fish Biological: FAST fish mCyp c 1 Biological: Placebo Phase 2

Detailed Description:

Fish allergy is a persistent food allergy (usually lifelong) which can be life threatening due to the danger for anaphylaxis (severe allergic reaction) upon accidental exposure to fish. Until today there is no curative treatment for fish allergy. The only treatment is avoidance. Patients with fish allergy have to avoid fish of all types and carry an adrenaline autoinjector and rescue medication, in case of accidental exposure to fish. That way patients with fish allergy have to continuously control what they are eating and this causes a great deal of stress and impacts their quality of life.

The major allergen responsible for fish allergy is the protein parvalbumin. It is recognized by the vast majority (96-100%) of fish allergic patients.

During the past, treatment of food allergy with immunotherapy was successful but dangerous, due to serious side effects (anaphylaxis).

A novel biotechnological product, a recombinant hypoallergenic parvalbumin, called mCyp c 1, is used for the first time in a phase IIb clinical trial, to test the efficacy of subcutaneous immunotherapy for the treatment of fish allergy. The investigational medicinal product mCyp c1, is based on the recombinant wild type carp parvalbumin (rCyp c 1) and is the result of site directed mutagenesis, by which the disruption of the two calcium binding sites of carp parvalbumin is performed. The modified parvalbumin mCyp c 1, is both hypoallergenic and immunogenic. That way it is a promising molecule for the safe and effective treatment of fish allergy.

This molecule has proven to be safe in a phase I/IIa study that has been performed, during which mCyp c 1 was administered with subcutaneous injections. During this study only local reactions at the injection site were observed. There were no observed systemic reactions. Even more, there were clear indications that mCyp c 1 was recognized by the immune system. The results of this phase I/IIa study guarantee the necessity of a phase IIb clinical trial with mCyp c 1, in order to study the efficacy of this modified parvalbumin in the treatment of fish allergy.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multinational Phase IIb Study to Investigate the Efficacy and Safety of Subcutaneous Immunotherapy With a Modified Fish- Parvalbumin Given in Single Rising and Maintenance Doses to Subjects Allergic to Fish
Study Start Date : October 2015
Actual Primary Completion Date : February 2017
Actual Study Completion Date : April 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Allergy

Arm Intervention/treatment
Experimental: FAST fish mCyp c 1

Subcutaneous injections of investigational medicinal product mCyp c 1 formulated in a solution (suspension) with aluminium.

Up-dosing (build-up) phase: each subject will receive 10 injections of active or placebo treatment. The first three injections will be given on the first day. For those on active treatment the dosing will begin at 6ng and conclude on week 8 with the administration of 60μg.

Maintenance phase: the maintenance dose of 60μg will be repeated once at two weeks and then monthly for a period of four months (four monthly injections).

Biological: FAST fish mCyp c 1
Subcutaneous immunotherapy
Other Name: mCyp c 1

Placebo Comparator: Placebo
Subcutaneous injections of exactly the same dosage, frequency and duration as Active Arm but all injections will be performed with placebo (has the same composition as the active drug suspension but no allergen mCyp c 1 is added).
Biological: Placebo
Subcutaneous immunotherapy




Primary Outcome Measures :
  1. Efficacy of subcutaneous immunotherapy with mCyp c 1 for the treatment of fish allergy (change from baseline in the threshold of fish protein that induces an allergic reaction) [ Time Frame: 7 months after treatment begining ]
    The primary outcome measure will be efficacy as determined by the change from baseline in the threshold of fish protein that induces an allergic reaction. This threshold will be assessed by means of a standardized double blind placebo controlled food challenge (DBPCFC) with cod-fish after completion of six months of immunotherapy. Success is defined as a statistically significant change in the threshold dose of protein that provokes a reaction in DBPCFC.


Secondary Outcome Measures :
  1. Safety (recording of adverse events)- Number of participants with adverse events and recording of the nature of adverse events [ Time Frame: Up to 13 months ]
    The fundamental secondary endpoint will be safety as indicated by clinical safety and tolerability and by the careful recording of adverse events; other surrogates of safety will be: physical examination, vital signs, 12-Lead ECG and laboratory evaluations.

  2. Severity of reaction in food challenge [ Time Frame: 7 months after treatment begining ]
    To study any possible change from baseline in the severity of the reaction in the baseline Double Blind Placebo Controled Food Challenge (DBPCFC) after treatment with mCyp c 1

  3. Skin prick test (SPT) reactivity [ Time Frame: 7 months after treatment begining ]
    To study any possible change(s) from baseline in skin prick test (SPT) reactivity against fish and mCyp c 1 (titrated) after treatment with mCyp c 1

  4. Serum specific IgE, IgG, IgG4 and IgA antibodies [ Time Frame: 7 months after treatment begining ]
    To study any possible change(s) from baseline in serum specific IgE, IgG, IgG4 and IgA antibodies against fish and rCyp c 1 (ImmunoCAP) after treatment with mCyp c 1

  5. Biological activity of IgE [ Time Frame: 7 months after treatment begining ]
    To study any possible change from baseline in the biological activity of IgE (stripped basophil histamine release test) after treatment with mCyp c 1



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject having given a written informed consent before completing any study related procedure.
  • Male or female subject from 18 to 65 years old and in general good health as determined by past medical history and physical examination.
  • For woman of child bearing potential:

    • a negative urine pregnancy test at screening visit,
    • the subject must receive/ use a medically effective contraceptive method during the study.
  • Convincing case history of allergy (immediate allergic reaction ≤ 2 hours) to fish ingestion.
  • Specific IgE to fish by both a positive (3mm mean wheal diameter over negative control) SPT to cod extract and an ImmunoCAP ≥ class 2 (0.70 kUA/L) for cod (f3) and rCyp c 1 at screening.
  • Positive DBPCFC with cod at screening visits.
  • FEV1 ≥ 80% of predicted values at screening.
  • Subject accepting to comply fully with the protocol.

Exclusion Criteria:

  • Placebo-reaction in DBPCFC.
  • Food anaphylaxis: anaphylactic shock (a score of 2 or 3 on cardiovascular/ neurologic symptoms according to PRACTALL (1): score 2 = drop in blood pressure and/or >20% from baseline, or significant change in mental status- score 3 = cardiovascular collapse, signs of impaired circulation/ unconscious) due to fish intake, both during the past and at screening DBPCFC.
  • Ongoing immunotherapy (IT) with any kind of allergen.
  • Ongoing or previous treatment with omalizumab.
  • Any clinical condition that contraindicates IT (EAACI guidelines) (8): serious immunological diseases, major cardiovascular disease, cancer, chronic infections, lack of compliance and severe psychological disorders.
  • Any significant clinical condition that the investigators judged might hamper the patient's safety or the study outcomes. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, haematological disease, neurological disease, mental disease, immunological and endocrine disease.
  • Chronic urticaria.
  • Severe atopic dermatitis or non-controlled atopic dermatitis.
  • Ongoing treatment with betablockers, angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor II antagonists (ARA II).
  • Pregnancy or nursing.
  • Uncontrolled asthma (asthma, if present, should be well controlled according to GINA guidelines using any kind of drugs except oral corticosteroids and omalizumab).
  • An FEV1<80% of predicted value during screening spirometry.
  • Subject who has participated in a clinical trial within 3 months prior to this one.
  • Subject with a history of drug or alcohol abuse.
  • Investigators, co-investigators, as well as their children or spouses and all the study collaborators should not be enrolled in the study.
  • Patients with concurrent allergy symptoms can be included if patients can manage without antihistamines and/or leukotriene receptor antagonists five days prior each screening and treatment visit.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02382718


Locations
Layout table for location information
Denmark
National University Hospital NUHD Denmark
Gentofte, Denmark, DK-2900
Odense University Hospital OUH Denmark
Odense, Denmark, DK 5000
Greece
Sotiria General Hospital for the Diseases of the Thorax
Athens, Greece, 115 27
Iceland
Landspitali University Hospital Reykjavik LSH Iceland
Reykjavik, Iceland, 101
Netherlands
Universitiy Medical Centre Utrecht UMCU The Netherlands
Utrecht, Netherlands, 85500
Poland
Medical Universtity of Lodz
Lodz, Poland
Spain
Hospital Universitario Reina Sofia (Cordoba) Spain
Cordoba, Spain, 14004
Hospital Clinico San Carlos SERMAS Spain
Madrid, Spain, 28040
Hospital Regional Universitario de Malaga Spain
Malaga, Spain
Sponsors and Collaborators
George Stavroulakis
Hospital San Carlos, Madrid
Odense University Hospital OUH Denmark
Medical Universtity of Lodz
National and Kapodistrian University of Athens
Landspitali University Hospital
National University Hospital NUHD Denmark
Universitiy Medical Centre Utrecht UMCU The Netherlands
Hospital Universitario Reina Sofia (Cordoba) Spain
Hospital Regional Universitario de Malaga Spain
Investigators
Layout table for investigator information
Study Chair: Ronald van Ree, Professor FAST Consortium under EU 7th FP

Additional Information:
Layout table for additonal information
Responsible Party: George Stavroulakis, On behalf of the FAST Consortium: George Stavroulakis, MD, Allergist, Clinical Coordinator FAST phase IIb study, University of Athens
ClinicalTrials.gov Identifier: NCT02382718     History of Changes
Other Study ID Numbers: FAST2015
First Posted: March 9, 2015    Key Record Dates
Last Update Posted: June 12, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by George Stavroulakis, University of Athens:
fish allergy
parvalbumin
immunotherapy
mCyp c 1

Additional relevant MeSH terms:
Layout table for MeSH terms
Hypersensitivity
Food Hypersensitivity
Immune System Diseases
Hypersensitivity, Immediate
Immunologic Factors
Physiological Effects of Drugs